ArticleJournal of medical virology2026
Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimChronic hepatitis B (CHB) affects over 250 million people globally and is a major contributor to liver complications, including cirrhosis and hepatocellular carcinoma (HCC). Though antiviral therapies suppress HBV, the rising prevalence of metabolic-associated steatotic liver disease (MASLD) poses new challenges. This study assessed how MASLD influences liver-related outcomes, fibrosis progression, and survival in CHB patients undergoing nucleus(t)ide analogs (NAs) therapy, using large-scale data and clinical cohort analysis.
methodsA retrospective study using the TriNetX US Collaborative Network, CHB patients receiving long-term NA therapy with undetectable serum HBV DNA and concomitant MASLD (CHB-MASLD-NA, n = 5600) were compared with those without MASLD (CHB-non MASLD-NA, n = 11 021), matched 1:1 by propensity scores (n = 4761 each after matching). Primary outcomes included 10-year incidence of HCC and cirrhosis, with survival assessed via Kaplan-Meier curves and hazard ratios (HRs) from Cox models. Separately, a clinical cohort of 64 CHB patients and 137 MASLD-only patients was assessed for steatosis (controlled attenuation parameter, CAP) and fibrosis (liver stiffness).
resultsAnalysis revealed that co-existing MASLD significantly compromised clinical outcomes. CHB-MASLD-NA patients faced a substantially higher risk of developing cirrhosis or HCC (HR 1.75, 95% CI 1.53-2.00, p < 0.001) and demonstrated lower 10-year survival rates (61.5% vs. 79.3%, p < 0.001) compared to the non-MASLD group. These findings were corroborated by the clinical cohort, where CHB-MASLD-NA patients exhibited greater liver stiffness (9.85 vs. 4.95 kPa) and a higher prevalence of advanced fibrosis compared to CHB alone and MASLD-only groups (28.0% vs. 14.3% and 4.4%). HBV DNA load was not a significant predictor of outcomes in this population (HR 1.00). Notably, as steatosis worsened, the pro-inflammatory cytokine TNF-α increased more sharply (3.73-fold) than the antiviral cytokine IFN-γ (2.13-fold).
conclusionsMASLD drives fibrosis and mortality in NA-treated CHB patients, as metabolic inflammation overrides the benefits of viral suppression. Integrated management, combining antiviral therapy, metabolic intervention, and immune monitoring, is essential to accurately assess progression and improve long-term prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.